MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer

  • MediWound Ltd MDWD has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). 
  • In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel. 
  • MediWound expects that data from both studies will be available by the end of 2021.
  • The 32-subject study is designed to evaluate the safety and tolerability of MW005 in BCC using different schedules of administration, as well as to provide a preliminary evaluation of its efficacy, as measured by the percentage of target lesions with complete histological clearance. 
  • The investigator-initiated trial will evaluate the safety and efficacy of MW005 in removing non-melanoma skin cancers and pre-cancerous lesions in up to 50 patients.
  • Price Action: MDWD shares traded higher by 0.77% at $3.93 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPhase 2 TrialSkin Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!